Novacyt S.A
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive h… Read more
Novacyt S.A (NVYTF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.118x
Based on the latest financial reports, Novacyt S.A (NVYTF) has a cash flow conversion efficiency ratio of -0.118x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.20 Million) by net assets ($60.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Novacyt S.A - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Novacyt S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Novacyt S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novacyt S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CIG PANNONIA LIFE INSURA.
F:0CKA
|
N/A |
|
Zuari Agro Chemicals Limited
NSE:ZUARI
|
0.202x |
|
Bewi Asa
OL:BEWI
|
0.034x |
|
Junee Limited Ordinary Shares
NASDAQ:JUNE
|
-0.059x |
|
Metal Sky Star Acquisition Corporation Ordinary shares
NASDAQ:MSSA
|
N/A |
|
Q32 Bio Inc
NASDAQ:QTTB
|
0.229x |
|
Healthcare Integrated Technologies Inc
PINK:HITC
|
-0.077x |
|
Hantech Bio-Technology Co., Ltd.
TWO:1294
|
N/A |
Annual Cash Flow Conversion Efficiency for Novacyt S.A (2011–2024)
The table below shows the annual cash flow conversion efficiency of Novacyt S.A from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $47.88 Million | $-9.82 Million | -0.205x | +28.38% |
| 2023-12-31 | $87.24 Million | $-24.99 Million | -0.286x | -140.40% |
| 2022-12-31 | $115.22 Million | $-13.73 Million | -0.119x | -207.71% |
| 2021-12-31 | $141.81 Million | $15.69 Million | 0.111x | -83.81% |
| 2020-12-31 | $150.71 Million | $102.98 Million | 0.683x | +1029.33% |
| 2019-12-31 | $12.47 Million | $-916.70K | -0.074x | -18.83% |
| 2018-12-31 | $18.15 Million | $-1.12 Million | -0.062x | +66.82% |
| 2017-12-31 | $22.12 Million | $-4.12 Million | -0.186x | -29.43% |
| 2016-12-31 | $15.15 Million | $-2.18 Million | -0.144x | +71.63% |
| 2015-12-31 | $7.77 Million | $-3.95 Million | -0.508x | -1099.81% |
| 2014-12-31 | $16.04 Million | $-678.92K | -0.042x | +90.85% |
| 2013-12-31 | $1.94 Million | $-897.54K | -0.462x | -236.32% |
| 2012-12-31 | $1.34 Million | $-184.36K | -0.138x | -121.29% |
| 2011-12-31 | $-744.73K | $-481.00K | 0.646x | -- |